Estrogens are well known to play a mitogenic role in breast cancer via direct activation of ERα and endocrine therapy (ie, Selective ER Modulators, ER‐antagonists, and aromatase inhibitors) are the main form of targeted therapy for these tumors. This evidence concerns the gene CYP19A1 and breast carcinoma.